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A B S T R A C T
Purpose: To estimate the cost-effectiveness of ruﬁnamide relative to topiramate and lamotrigine as
adjunctive treatment for children with Lennox–Gastaut Syndrome (LGS).
Methods: A Markov decision analytic model was developed to estimate the incremental cost-
effectiveness ratio over a three-year time horizon in patients with LGS uncontrolled by up to three
antiepileptic drugs. Utilities were assigned to health states, deﬁned according to a patient’s response to
treatment (75%, 50% and <75%, and <50% reduction in tonic–atonic [drop attack] seizure frequency
and death). Efﬁcacy and safety estimates were made using indirect/mixed-treatment comparisons of
data obtained from published literature. Outcomes included costs and quality-adjusted life-years
(QALYs), allowing the incremental cost-effectiveness ratio to be estimated as cost per QALY gained.
Results: Over three years, the total cumulative costs for ruﬁnamide, topiramate, and lamotrigine were
£24,992, £23,360, and £21,783, respectively. Ruﬁnamide resulted in an incremental QALY gain of 0.079
relative to topiramate and 0.021 relative to lamotrigine. The incremental costs of ruﬁnamidewere £1632
and £3209, relative to topiramate and lamotrigine, resulting in an incremental cost per QALY gained of
£20,538 and £154,831, respectively.
Conclusions: Considering the underlying assumptions, this current economic evaluation demonstrates
that ruﬁnamide is likely to be a cost-effective alternative to topiramate as adjunctive treatment for
children with LGS in the UK. In addition, when compared to lamotrigine, which is an inexpensive
treatment, ruﬁnamide should be considered as a cost-effective alternative due to the importance of
patient choice and equity of access in such a rare and devastating condition.
 2009 British Epilepsy Association. Published by Elsevier Ltd. All rights reserved.
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Lennox–Gastaut Syndrome (LGS) is a rare and severe form of
childhood epileptic encephalopathy characterized by the presence
of multiple seizure types, generalized discharges with slow spike-
and-wave complexes in the electroencephalogram, and mental
deﬁciency or learning difﬁculties.1–3 The pathophysiology of LGS is
varied; in many cases, its aetiology is unknown, although some
causes include brain abnormalities and prenatal or neonatal brain
injury. LGS accounts for 1–4% of all childhood epilepsies.4 With a
reported prevalence of 0.9 cases per 10,000 population across all
age groups,4,5 LGS has been classiﬁed by the European Medicines* Corresponding author at: Eisai Europe Limited, European Knowledge Centre,
Mosquito Way, Hatﬁeld, Hertfordshire, AL10 9SN, UK. Tel.: +44 0 845 676 1228;
fax: +44 0 845 676 1401.
E-mail address: Lara_Verdian@eisai.net (L. Verdian).
1059-1311/$ – see front matter  2009 British Epilepsy Association. Published by Else
doi:10.1016/j.seizure.2009.10.003Agency (EMEA) and US Food and Drug Administration (FDA) as an
orphan disease since 2004.6,7
LGS is considered to be a catastrophic illness. In addition to the
developmental disability experienced by patients with LGS,
seizures are intractable and physically damaging, further inter-
fering with the patient’s intellectual and social development.
Catastrophic epilepsies presenting during the childhood develop-
mental stage halt cognitive and social development, leading to
long-term effects.8 LGS therefore represents a signiﬁcant burden to
both patients and their carers. Furthermore, while LGS-related
healthcare costs have not been studied speciﬁcally, the direct
lifetime costs for a patient in the US with intractable and frequent
seizures is estimated to be almost $140,0009; therefore, the
economic burden per patient with LGS can be reasonably assumed
to be signiﬁcant.
Seizures characteristic in LGS include tonic, atonic, atypical
absence, myoclonic, clonic, and partial absence, with unclassiﬁed
seizures also present.10 Due to the difﬁculty in differentiatingvier Ltd. All rights reserved.
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clinical studies of LGS and termed tonic–atonic seizures or ‘drop
attacks’. These drop attacks are the most physically damaging
seizures causing recurrent injuries such as lacerations or head
injuries due to falls.10 As a result, many patients require constant
supervision, often need protective headwear, or are conﬁned to
wheelchairs. The reduction in drop attack seizure frequency is
therefore considered one of the most clinically signiﬁcant out-
comes for patients with LGS.11
LGS is a difﬁcult-to-control condition, with considerable
uncertainty regarding the optimum therapy12 and little available
guidance to assist specialist physicians in choosing appropriate
antiepileptic drugs (AEDs).13 There is currently no cure for LGS and,
since existing treatments seldom offer complete control of
seizures, treatment goals are to provide the best control of
seizures, using the fewest AEDs, while limiting any adverse
events.14,15 Moreover, the development of novel therapeutic
agents for treating LGS is hindered by the absence of an
appropriate animal model; as a result, treatment options for this
devastating condition are severely limited.13
Current ﬁrst-line treatment involves the use of traditional AEDs
(including valproate); none ofwhich has been rigorously studied in
controlled clinical trials in a population of patients with LGS.
Treatment with these traditional AEDs rarely provides sufﬁcient
control of seizures, and newer AEDs are added to achieve a more
effective combination therapy.16 Newer AEDs, such as topiramate
(TPM), lamotrigine (LTG), and felbamate, have demonstrated
efﬁcacy as adjunctive treatments for patients with LGS in
randomized, placebo-controlled clinical trials.17–19 In the UK, only
TPM and LTG are licensed for the adjunctive treatment of patients
with LGS. The use of adjunctive felbamate is limited to a ‘named
patient’ basis and its use is restricted to last-line therapy due to the
risk of life-threatening adverse events such as aplastic anemia and
hepatitis.20,21
Newer AEDs are considered to offer an improved side effect
proﬁle relative to older agents; however, those commonly used for
adjunctive use in LGS are not free from adverse events. Life-
threatening skin reactions such as Stevens–Johnson Syndrome
have been associated with LTG20, while TPM is associated with
impaired cognition22 and weight loss.23
The effects of TPMon cognition include impaired concentration,
confusion, memory loss, psychomotor slowing, and speech
disorder.24 Since the impact of LGS on cognition is also well
documented,8 with patients often experiencing reduced alertness
after seizures and being less responsive between seizures,
medications that potentially compound the inherent cognitive
disability seen in LGS would be undesirable to both caregivers and
patients. Similarly, patients with LGS are often underweight and
more prone to illness, as frequent seizures and constant physical
activity utilize energy, resulting in both difﬁculties in eating and
fatigue. Consequently, LGS treatments that induce a loss of
appetite and weight loss, such as felbamate21 and TPM,23 can
exacerbate the problems associated with being underweight,
having a profound impact on patient well-being. Weight loss
associated with TPM is particularly marked, to the extent that it
has been extensively studied as a treatment for obesity.25
Despite these undesirable adverse events, many patients with
LGS often persist with their treatment due to the lack of alternative
options. This situation highlights the need to develop new AEDs
that are both effective in treating the multiple seizure types
associated with LGS, and which also have an improved tolerability
proﬁle.
Ruﬁnamide (RUF) is a structurally distinct AED licensed as
adjunctive therapy for patients with LGS aged four years and over.
RUF principally acts by prolonging the inactive state of sodium
channels, inhibiting the ﬁring of sodium-dependent actionpotentials.26 A Phase III, double-blind, placebo-controlled clinical
trial has shown RUF to be effective in reducing seizure frequency in
patients with LGS.15 RUF was signiﬁcantly more effective than
placebo in reducing total seizure frequency (32.7% reduction
versus 11.7%, respectively, p = 0.0015) and drop attacks (42.5%
reduction versus 1.4% increase, respectively, p = 0.0041). Further-
more, a signiﬁcantly higher proportion of patients receiving RUF
achieved greater than 50% reduction in total seizure frequency,
compared with placebo (31.1% of patients versus 10.9%, respec-
tively, p = 0.0045). This study also demonstrated that RUFwas well
tolerated, with the most commonly reported adverse events
(including somnolence, vomiting, pyrexia, and diarrhea) being
mild in intensity.15 Importantly, a separate study also showed that
RUF does not adversely affect cognition, even at high therapeutic
doses.27
As newer drugs are often more costly than existing therapies,
andmay offer only marginal beneﬁts, it is important that decision-
makers are able to effectively assess the value of new treatments
relative to existing therapies. Health technology assessment
bodies in the UK (e.g., the National Institute for Health and
Clinical Excellence [NICE] and the Scottish Medicines Consortium
[SMC]) prefer to measure cost-effectiveness in terms of cost per
quality-adjusted life-year (QALY).28 This allows comparisons of
cost-effectiveness across therapeutic areas and provides ameasure
of the opportunity costs of new health technologies. In the UK,
NICE does not use an absolute willingness to pay (WTP) threshold
in its cost-effectiveness analyses of new technologies, but
generally considers a WTP threshold range of £20,000 to
£30,000 per QALY as an acceptable incremental cost-effectiveness
ratio (ICER). In cases where new therapeutic interventions possess
an ICER in excess of £20,000 per QALY, threshold factors such as
uncertainty around the point estimate of the ICER, adequately
captured evidence on improvements in health-related quality of
life, and the innovative nature of the new technology are taken in
account. In situations where an ICER exceeds £30,000 per QALY, a
stronger case, in regard to the factors listed, is necessary in order
for NICE to deem the intervention an effective use of NHS
resources.38
This method of appraisal often poses challenges for orphan
drugs, for which the price and cost-effectiveness estimates are
generally high,29,30 and for which any economic analysis often
relies heavily upon assumptions and evidence synthesis due to the
paucity of appropriate clinical data. In addition, there may also be
no validated disease-speciﬁc tools to assess health-related quality
of life or, due to the rarity of orphan diseases, small clinical study
samples make it difﬁcult to make meaningful assessments of
improvements in health-related quality of life with new inter-
ventions.
The objective of this study was to evaluate the cost-effective-
ness of RUF relative to TPM and LTG as adjunctive treatment for
children with LGS in the UK.
2. Methods
2.1. Model structure
A Markov decision analytic model was developed to estimate
the cost-utility of RUF versus TPM (or LTG) as adjunctive treatment
for a hypothetical cohort of patientswith LGS uncontrolled by up to
three AEDs (Fig. 1). In economic decision analytic models,
mathematical relationships are used to deﬁne a series of possible
consequences that would stem from the set of alternative options
being evaluated.31
Markov models are commonly used in health economic
decision analyses, and are particularly well suited to modeling
the progression of chronic diseases. For such analyses, the disease
Fig. 1.Markov decision analytic model structure. Abbreviations: RUF, ruﬁnamide; TPM, topiramate; LTG, lamotrigine; WC75, drop attacks are really well controlled (75%
reduction in drop attacks from baseline); WC50, drop attacks are well controlled (50% and <75% reduction in drop attacks from baseline); NC, non-responders where drop
attacks are not well controlled (<50% reduction in drop attacks from baseline).
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states, and a probability is assigned for the transition between the
health states over a discrete time period, or cycle. Estimates of
resource use and health outcome consequences are applied to each
health state and transitions in the model. Subsequent running of
the model over a large number of cycles generates an estimate of
the long-term costs and beneﬁts of a particular healthcare
intervention.31
In the present analysis, patients entering the model are
administered RUF, TPM or LTG as an adjunctive treatment for a
three-month time period. At follow-up, patients who have
remained on their initial adjunctive therapy are classiﬁed into
health states representing their response to adjunctive AED
treatment: WC75—drop attacks are really well controlled (75% reduction
in drop attacks from baseline). WC50—drop attacks are well controlled (50% and <75%
reduction in drop attacks from baseline). NC—non-responders where drop attacks are not well controlled
(<50% reduction in drop attacks from baseline).
At the end of the ﬁrst three months, patients may have also
either switched to standard treatment due to adverse events or
have died.
Patients then enter a maintenance phase of three-month cycles
in which they can transition between health states (WC75, WC50,
NC, and death). Patients who enter the NC state can switch to
standard treatment, and then enter a separate Markov structure.Patients on standard treatment receive amix of AEDs as used in the
placebo arm of the RUF clinical trial.15
The health state descriptions focus on the impact of drop
attacks on the daily life of children with LGS as these were
deemed to be the most impactful and clinically relevant
measures. Each health state was developed based on an
extensive literature review, validation by expert physicians,
and pilot interviews.32 The seizure reduction thresholds applied
to the health states are consistent with those used as standard
practice in clinical studies of AEDs in LGS,15,17,18 and are
recognized by the EMEA as a valid endpoint for evaluating the
efﬁcacy of AEDs.33
2.2. Time horizon
LGS is a chronic, life-long disease and, ideally, an economic
model should possess a lifetime horizon to capture lifetime costs
and outcomes. A time horizon of three years was adopted in the
base case analysis because the maximum follow-up was 36
months in the RUF study and 1225 days (approximately 40
months) in the TPM extension study.15,18 In order to accurately
extrapolate beyond the data from randomized studies, it is
important to have good evidence regarding the natural history
of the disease, in terms of the deﬁned health states.34 While the
long-term prognosis of patients with LGS is poorly documented,
the limited available evidence suggests that seizure types and the
clinical picture of LGS may evolve as children reach adulthood.
Tonic seizures tend to become the dominant seizure type over
time, while slow spike-and-wave patterns tend to resolve.35,36
Table 1
Patient distribution probability across model transition states and probability of patients discontinuing treatment due to adverse events, after three months.
Outcome RUF TPM LTG
Base case 95% CI Base case 95% CI Base case 95% CI
WC75 0.214 0.131–0.316 0.082 0.008–0.421 0.044 0.005–0.198
WC50 0.200 0.119–0.301 0.156 0.035–0.496 0.270 0.102–0.542
Discontinuation due to adverse events 0.077 0.030–0.153 0.003 0.000–0.746 0.001 0.000–0.026
RUF, ruﬁnamide; TPM, topiramate; LTG, lamotrigine; WC75, drop attacks are really well controlled (75% reduction in drop attacks from baseline); WC50, drop attacks are
well controlled (50 and <75% reduction in drop attacks from baseline); CI, conﬁdence interval.
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2.3. Data source: efﬁcacy and safety
An extensive literature search identiﬁed three randomized,
double-blind, placebo-controlled trials, one each for RUF,15 TPM,18
and LTG17 for themanagement of LGS. These clinical trials were the
only controlled studies of each drug in an LGS population identiﬁed
by the literature search. In the absence of any head-to-head data
directly comparing RUF, TPM, and LTG for treating LGS, Bayesian
indirect or mixed-treatment comparisons, using a ﬁxed-effects
model, were used for comparator analysis to estimate the short-
term (three months) health state transition probabilities, and
probabilities of discontinuation due to adverse events (Table 1).
Ideally, direct evidence from robust randomized controlled
trials should be used to inform economic analyses; however, in the
absence of direct head-to-head studies, indirect comparisons are
considered appropriate to estimate the comparative effectiveness
of different treatments.37,38 In the majority of cases, results
generated using adjusted indirect comparisons have been shown
to be consistent with the results of head-to-head randomized
controlled trials.39,40
Adjusted indirect, or mixed-treatment comparisons are a
generalization of a traditional pair-wise meta-analysis, including
multiple pair-wise comparisons. This analysis preserves the
randomized treatment comparison within trials, while combining
available comparisons between treatments.41 Due to the avail-
ability of only one study per drug treatment, a ﬁxed-effects model
was chosen instead of a random-effects model.
The long-term transition probabilities for RUF therapy were
derived from the clinical trial open-label extension data.15 In the
open-label extension phase of the TPM clinical study, primary
clinical outcomes were deﬁned as responses in the last three orTable 2
Drug acquisition costs according to the British National Formulary 54th Edition.
Medication Average dosea (mg/kg) Daily doseb (mg)
Ruﬁnamide 40.20 1700
Topiramate 8.30 351
Lamotrigine 5.30 224
Valproate 36.00 1523
Clonazepam – 1.4
Clobazam – 21.9
Carbamazepine 25.00 1058
Phenytoin 7.50 317
Phenobarbitone 7.50 317
a Derived from an expert panel survey.
b Based on mean weight 42.3 kg.six months since the patients had been receiving TPM, and hence
were not directly comparable to outcomes in the RUF trial. In
addition, the LTG trial did not have an open-label extension
focusing on LGS patients only. Patients from the short-term,
randomized LTG study entered a mixed group open-label
extension with patients from other LTG trials, for which
outcomes were not reported by patient type. Consequently,
the TPM and LTG long-term transition probabilities were also
based on the RUF study.
2.4. Data source: health state utilities
Since therewere no appropriate published data reporting utility
values for patients with LGS, a separate study was performed to
elicit utilities for the LGS health states, among the UK general
public.32 Utilities were elicited primarily using the time trade-off
(TTO) exercise, a method commonly used for utility generation in
cost-effectiveness analyses.42
2.5. Data source: resource utilization and costs
This cost-utility study was performed from the perspective of
the UK National Health Service (NHS) and Personal Social Services.
Only direct healthcare costs, which included drug acquisition, NHS
resource use, inpatient stay, diagnostic procedures, personal social
services, and the costs associated with treating adverse events,
were utilized. Drug acquisition costs for RUF, TPM, and LTG,
together with the cost of background standard treatments and
standard treatment after switching, were calculated based on
mean daily dose and costs presented in the British National
Formulary 54th Edition43 (Table 2). Estimates of healthcare
resource use were obtained through a survey of physicians
specializing in pediatric epileptology. Medical resource costs,
and costs due to adverse events, were calculated according toTablets per day Price per tablet (£) Cost per day (£)
1 (100mg) 0.86 6.58
4 (400mg) 1.43
1 (50mg) 0.54 3.30
3 (100mg) 0.92
1 (25mg) 0.09 0.56
2 (100mg) 0.24
3 (500mg) 0.23 0.69
3 (0.5mg) 0.04 0.12
2 (10mg) 0.33 0.65
2 (200mg) 0.13 0.72
2 (400mg) 0.24
3 (100mg) 2.23 6.75
5 (60mg) 0.03 0.13
Table 3
Resource utilization unit costs.
Resource use Cost per unit (£) Description of unit Source
NHS contacts
GP visits 34.00 Per consultation PSSRU 2007
Nurse visits 22.00 Per consultation PSSRU 2007
Specialist visits 30.00 Per hour PSSRU 2007
Neurologist visits 115.00 Per hour PSSRU 2007
Pediatric epileptologist 115.00 Per hour PSSRU 2007
Clinical psychologist 30.00 Per hour PSSRU 2007
Pediatrician 115.00 Per hour PSSRU 2007
Learning disability specialist 115.00 Per half hour PSSRU 2007
Inpatient stay
ICU per day 550.00 Per day PSSRU 2007
General ward per day 236.00 Per day PSSRU 2007
Attending A&E department 95.00 Per attendance PSSRU 2007
Personal social services
Occupational therapy 95.00 Per contact NHS Reference Costs 2006–07
Psychotherapy 235.00 Per session NHS Reference Costs 2006–07
Respite care 131.00 Per contact NHS Reference Costs 2006–07
Home care 94.00 Per day GMB Surveya
Diagnostic procedures
EEG-normal, short 100.00 Per test NHS Reference Costs 2006–07
EEG-24h 100.00 Per test NHS Reference Costs 2006–07
EEG-video, short 100.00 Per test NHS Reference Costs 2006–07
EEG-video, 24h 100.00 Per test NHS Reference Costs 2006–07
MRI 244.00 Per scan NHS Reference Costs 2006–07
CT 129.00 Per scan NHS Reference Costs 2006–07
PET 12.00 Per test NHS Reference Costs 2006–07
Blood test 3.00 Per test NHS Reference Costs 2006–07
a Estimation based on an average gross hourly pay of £11.69 for full/part-time men and women in Scotland working 8h per day (GMB Briton’s General Union—average
hourly pay in 81 out of 204UK areas below 90% of UK average of £12.50 per hour 2005).65 GP, general practitioner; ICU, intensive care unit; A&E, accident and emergency; EEG,
electroencephalogram; MRI, magnetic resonance imaging; CT, computed tomography; PET, positron emission tomography.
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National Health Service Reference Costs 2006–200745 (Table 3).
Adverse events were assumed to occur only within the ﬁrst three
months of treatment initiation; therefore, these costs were limited
to this period. In line with UK Health Technology Assessment
(HTA) requirements, an annual discount rate of 3.5% was used for
both costs and beneﬁts.
2.6. Outcomes
The outcome parameters of the present analysis were QALYs,
drug acquisition costs, other medical costs (i.e., those associated
with NHS contacts, inpatient stays, personal social services, and
diagnostic procedures), costs associated with adverse events, and
total costs. From these outcomes cost-effectiveness was estimated
using the incremental cost per QALY and net monetary beneﬁt
(NMB) of RUF relative to each comparator.
2.7. Assumptions
The following assumptions were made in the cost-utility
analysis: The clinical trial populations within the three pivotal trials of
RUF,15 TPM,18 and LTG17 were representative of patients with
LGS in clinical practice. In the absence of head-to-head data comparing the three drug
treatments, Bayesian mixed-treatment comparisons accurately
represented the comparative efﬁcacy and safety of RUF, TPM, and
LTG. Transition probabilities, derived from the period between three
months and six months of the RUF trial, accurately represented
the movement of patients in the maintenance phase of the
model. Long-term (beyond three months) transition probabilities for
RUF (based on the open-label extension of the RUF study) were
applicable to TPM and LTG. Patients who were classiﬁed as non-responders (NC) would not
move to WC50 or WC75 health states if they persisted with the
same treatment. Adverse events only occurred during the ﬁrst three months
following the initiation of treatment. Daily dose of each treatment remained constant.
 The physician survey accurately represented the average
resource utilization of patients with LGS. The daily doses of concomitant non-comparator AEDs were
comparable across all treatment arms.
2.8. Base case analysis
The base case analysis primarily estimated the incremental
cost-utility ratio of adjunctive RUF relative to TPM over a three-
year horizon. The base case analysis also estimated the incre-
mental cost-utility ratio of RUF relative to LTG. The cost-utility
analysis of RUF versus LTG was secondary due to the paucity of
comparable efﬁcacy data for LTG.
2.9. Sensitivity analyses
Probabilistic sensitivity analysis was used to capture the
uncertainty in the input parameters. Uncertainty surrounding
input parameter estimates, such as efﬁcacy, safety, utilities, and
costs, are characterized by the limitations or absence of evidence
available to inform input parameters. Limitations of available
empirical studies may result from sampling problems (e.g., if not
all patients were measured), and this uncertainty can be expressed
as standard errors or 95% conﬁdence intervals. In the probabilistic
sensitivity analysis of the present economic model, uncertainty in
Table 4
Estimated costs (£) and beneﬁts (QALYs) of comparative treatments over 3 years.
RUF TPM LTG
Base case 95% CI Base case 95% CI Base case 95% CI
Treatment costs (£) 6,430 5777–7276 3,991 3526 to 4614 2,722 2664 to 2770
Total costs (£) 24,992 20,928–29,910 23,360 18,972 to 28,927 21,783 17,309 to 26,887
Total QALYs 1.44 1.30–1.59 1.36 1.21 to 1.53 1.42 1.27 to 1.57
Incremental costs of RUF (£) 1,632 189 to 3523 3,209 1392 to 4935
Incremental QALYs for RUF 0.079 0.039 to 0.179 0.021 0.081 to 0.120
Incremental cost (£) per QALY for RUF 20,538 154,831
RUF, ruﬁnamide; TPM, topiramate; LTG, lamotrigine; QALYs, quality-adjusted life-years; CI, conﬁdence interval.
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tion were expressed as beta-distributions, while uncertainties in
cost data were expressed as gamma-distributions.
A distribution of the incremental costs and beneﬁts (QALYs)
was determined by sampling a value from each input parameter
distribution, calculating the results with the model, then repeating
this process 1000 times. The results were presented with a point
estimate and 95% uncertainty intervals, as well as a joint-
distribution of incremental costs andQALYs on a cost-effectiveness
plane, illustrating the uncertainty surrounding the estimates of
incremental costs and QALYs. A cost-effectiveness plane is divided
into four quadrants. The south-east quadrant represents instances
where the intervention is more effective and less costly than the
comparators (dominates), with the opposite situation in the north-
west quadrant, where the intervention is more costly and less
effective than comparators (dominated). The north-east quadrant
represents interventions that are more costly yet more effective,
while the south-west quadrant represents less effective and less
costly interventions.46 Cost-effectiveness acceptability curves are
also constructed to show the probability that an intervention is
cost-effective compared with an alternative, for a given range of
WTP values.46 One-way sensitivity analysis was used to test the
uncertainty of model parameters when varied by 20%.
2.10. Scenario analysis
Uncertainty surrounding scenario judgments relates to
assumptions made in economic analyses for input data that
cannot be observed empirically. These include drug unit costs,
discount rates, and the time horizon considered. Uncertainty of
this nature is analyzed by means of multiple scenario analyses,
where a separate probabilistic analysis is performed for each
scenario.
The primary base case scenario estimated the incremental cost-
utility ratio of RUF relative to TPM and LTG, when used
adjunctively to standard care with a three-year time horizon. In
this primary scenario, both costs and beneﬁts were discounted at a
rate of 3.5%. Alternative scenarios investigated were: A time horizon of one year and ﬁve years.
 AFig. 2. Cost-effectiveness plane comparing RUF with TPM and LTG. Abbreviations:
RUF, ruﬁnamide; TPM, topiramate; LTG, lamotrigine; QALYs, quality-adjusted life-
years; GBP, Great British Pounds.pplying 0% and 6% discounting to both costs and beneﬁts.
3. Results
3.1. Base case analysis
Over the three-year time horizon, a greater proportion of
patients are assumed to achieve WC75 status with RUF treatment,
compared with TPM or LTG. On average, patients remained on RUF
for 1.67 years before switching to standard treatment, compared
with 1.64 and 1.69 years for TPM or LTG, respectively. After three
years, the discounted cumulative drug costs were highest for RUF,
although the medical resource costs and costs of treating adverseevents are expected to be lowest with this agent. Overall, RUF
would result in the highest costs over the three-year time horizon
(Table 4).
The total cumulative costs and associated QALYs for RUF, TPM,
and LTG, are shown in Table 4. The corresponding incremental cost
per QALY for the primary (RUF versus TPM) and secondary (RUF
versus LTG) analyses are also presented in Table 4.
3.2. Probabilistic sensitivity analysis
In the cost-effectiveness plane, the results scatter predomi-
nantly in the north-east quadrant, indicating that RUF is more
effective, but more expensive, than TPM and LTG (Fig. 2). Some
points, however, appear in the north-west and south-east
quadrant, suggesting that in some instances RUF is either
dominated by, or itself dominates, TPM and LTG. The wide
distribution of the results in the cost-effectiveness plane thus
reﬂects the uncertainty around the point estimate. Analysis of
the uncertainty was determined by sampling a value for each
input parameter distribution, calculating the results with the
model and repeating the process 1000 times. Analysis of the cost-
effectiveness estimate revealed that over 90% of the uncertainty
around costs and QALYs were attributed to the transition
probabilities of initial treatment (Fig. 3). Other medical costs
accounted for 7–10% of the uncertainty in costs, while utilities
explained approximately 1% of the uncertainty in QALYs, but had
little or no effect on costs.
The probability of RUF being cost-effective compared to TPM
and LTG for different WTP thresholds is indicated by the cost-
effectiveness acceptability curve (Fig. 4). At a WTP threshold of
£20,000, the probability that RUF is more cost-effective than TPM
or LTG is 52% and 8%, respectively. If a WTP of £30,000 is
considered, the corresponding probability of RUF being more cost-
effective than TPM or LTG rises to 65% and 15%, respectively.
Fig. 3.Uncertainty by covariates for RUF versus (A) TPM and (B) LTG in the base case
scenario (TTO utilities) Abbreviation: QALYs, quality-adjusted life-years.
Fig. 4. Cost-effectiveness acceptability curves for RUF, TPM and LTG using TTO
utilities. Abbreviations: RUF, ruﬁnamide; TPM, topiramate; LTG, lamotrigine;
QALYs, quality-adjusted life-years; GBP, Great British Pounds.
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The results of the model were most sensitive to changes in the
model health state transition probabilities during RUF, TPM, and
LTG treatment. Fig. 5 shows the RUF versus TPM model input
parameters which, when varied by 20%, led to a 10% change in
the ICER. The model was not sensitive to any of the remaining model
inputs, which when varied had relatively little impact on the ICER.
Fig. 6 shows the sensitivity of the RUF versus LTG model when input
variables were varied by 20% which resulted in a 10% change in
the ICER. Varying any remaining model inputs had relatively little
impact on the ICER estimate. In both the RUF versus TPM, and RUF
versus LTG analyses, the ICER was especially sensitive to thetransition probabilities of patients achieving and maintaining
WC75 status (Figs. 5 and 6, respectively).
3.4. Scenario analysis
Further analyses were performed to investigate the effects of
using alternative, time horizon, and discounting of both costs and
beneﬁts. The same incremental costs were used for each scenario
analysis. Alternative scenarios under different time horizons and
discount rates provided comparable results as the base case
analysis. Under each of the different scenarios the ICER of RUF
versus TPM remained below £29,000 and ICER of RUF versus LTG
remained over £154,000.
4. Discussion
In patients with LGS, whose disease is uncontrolled by up to
three AEDS, the incremental cost per QALY gained with RUF
therapy versus TPM or LTG, was £20,530 and £154,831,
respectively. Therefore, RUF may be considered to be a cost-
effective alternative to TPM as adjunctive treatment for patients
with LGS in the UK. In addition, in view of the importance of patient
choice and equity of access in such a rare and devastating
condition, RUF should be considered an effective alternative to
inexpensive LTG, for the adjunctive treatment of LGS.
There are very few treatment options available for LGS, with
current therapies being described as ‘difﬁcult and disappointing’.47
Current treatments have variable efﬁcacy and safety/tolerability
proﬁles in different patients, making them more appropriate for
some patients than others. As a result, providing treatment choice
for LGS is paramount.
Model-based health economic studies are commonly used to
integrate clinical efﬁcacy and safety data, with estimates of
resource utilization and productivity data, to assess the cost-
effectiveness of novel interventions. However, for epilepsy in
general, cost-effectiveness analyses for newer AEDs are con-
strained by a paucity of data, and the assessment of newer AEDs for
pediatric epilepsies is no exception. In the only published cost-
effectiveness analysis of newer AEDs focusing on children aged 3–
18 years, with a diagnosis of partial epilepsy with or without
primary generalization, it was concluded that insufﬁcient were
data available to accurately estimate the trade-offs between newer
and older AEDs.48
Only two studies have assessed the cost-effectiveness of
interventions for LGS. The ﬁrst is a study assessing the cost-
effectiveness of RUF in the treatment of LGS from a UK societal
perspective. Beneﬁts were measured in terms of the cost per 1%
increase in successfully treated patients (deﬁned as patients with
>50% reduction in the frequency of total seizures). RUF was
compared with TPM, LTG, and standard treatment in an individual
patient simulation model over a three-year horizon, reporting a
cost per 1% increase in successfully treated patients of £128 and
£2151when RUFwas comparedwith TPM and LTG, respectively.49
Relative to standard treatment, RUF treatment resulted in a
signiﬁcantly higher proportion of successfully treated patients;
therefore, the incremental cost-effectiveness of RUF compared
with standard therapy was £85 per 1% increase in successfully
treated patients.49
The second cost-effectiveness study estimated the cost per
single seizure reduction following surgical vagal nerve stimula-
tion.50 This study was performed in patients with LGS (aged 7–18
years), from a Dutch perspective, over a 24-month horizon and
showed that the cost required to prevent one seizure was
s16.93.50 Although this is not directly comparable to themeasures
of cost-effectiveness in the present study, the high number of
seizures experienced by LGS sufferers suggests the cost required to
Fig. 5. One-way sensitivity analysis of RUF versus TPM. Abbreviations: RUF, ruﬁnamide; TPM, topiramate; WC75, drop attacks are really well controlled (75% reduction in
drop attacks frombaseline);WC50, drop attacks arewell controlled (50% and<75% reduction in drop attacks frombaseline); NC, non-responderswhere drop attacks are not
well controlled (<50% reduction in drop attacks from baseline); Tx, treatment.
Fig. 6. One-way sensitivity analysis of RUF versus LTG. Abbreviations: RUF, ruﬁnamide; LTG, lamotrigine; WC75, drop attacks are really well controlled (75% reduction in
drop attacks frombaseline);WC50, drop attacks arewell controlled (50% and<75% reduction in drop attacks frombaseline); NC, non-responderswhere drop attacks are not
well controlled (<50% reduction in drop attacks from baseline).
L. Verdian, Y. Yi / Seizure 19 (2010) 1–118
L. Verdian, Y. Yi / Seizure 19 (2010) 1–11 9reduce a patient’s seizures by 50% over a three-year time horizon
would be relatively high.
Similarly, relatively few studieswere available to determine the
effectiveness of treatments for patients with generalized seizures
in an HTA performed for NICE.51 It was reported that newer AEDs
used adjunctively were more effective, yet more costly than
continuing with existing monotherapy treatments, and that
adjunctive therapy with newer AEDs may be cost-effective at a
WTP threshold of greater than £20,000 per QALY. Valproate and
LTG were shown to have similar clinical beneﬁts when used as
monotherapy, and adjunctive TPMwas deemed to be cost-effective
with an ICER of £34,500, relative to continuing with standard
monotherapy.51
There are also relatively few cost-effectiveness analyses
reporting a cost per QALY for newer AEDs for adjunctive therapy
in adults with refractory partial epilepsy.52–55 In the economic
analysis reported by Messori et al., the cost per QALY gained
following the adjunctive use of LTG (500 mg/day) relative to
placebo in patients with refractory epilepsy was estimated to be
$41,000.53 This economic analysis used a lifetime horizon and
considered direct costs derived from an analysis of the lifetime
costs of US patients with epilepsy diagnosed in 1990,56 and clinical
data were obtained from a six-month, randomized, double-blind,
placebo-controlled study of patients with refractory partial
seizures.57
Maltoni and Messori investigated the lifetime cost-effective-
ness of TPM (200 mg/day), as adjunctive therapy, relative to
placebo, in patients with refractory epilepsy uncontrolled by up to
two AEDs. The cost per QALY gained estimated in this analysis was
£21,353,52 using outcome data derived from a subgroup analysis of
a 12-week, randomized, placebo-controlled study.58 The analysis
used direct costs estimated in a UK setting from a societal
perspective. A secondary analysis, using an identical model to that
used for LTG by Messori et al.,53 considered two simulated cohorts
(adjunctive TPM versus adjunctive placebo), and estimated a cost
per QALY gained of £3893 and £22,833, relative to adjunctive
placebo, for TPM and LTG, respectively. The differences in the
classiﬁcation of health outcomes, and the handling of outcome
data in the secondary analysis, were noted as possible reasons for
the differences in the results.
Spackman et al.55 compared the cost-effectiveness of zonisa-
mide, relative to levetiracetam, for the adjunctive therapy of adult
partial seizures refractory to treatment with two or more AEDs.
The analysis used a Markov decision analytic model and was
performed from the perspective of the Scottish NHS over a 15-year
time horizon. Model outcomes were measured in QALYs gained
and only direct healthcare costs were included. The results of the
analysis estimated the incremental costs and QALYs as £20 and
0.026, respectively, for zonisamide relative to levetiracetam, giving
an ICER of £761 per QALY gained.
Finally, the analysis of adjunctive pregabalin (300 mg/day) in
patients with refractory epilepsy uncontrolled on at least one AED
estimated the cost-effectiveness over a one-year horizon in a US
setting. This analysis used a Markov model with clinical data
derived from the unpublished pregabalin clinical trials program.
The results showed that, relative to standard treatment, the cost
per QALY gained was estimated as $52,983.54
The results from these economic studies are not directly
comparable to the results from the present analysis of RUF for
treating LGS. For instance, health states and treatment outcomes
are not comparable as treatment outcomes in refractory partial
epilepsy are often described in terms of seizure-free days, whereas
seizure freedom is rarely achieved with LGS treatments. Moreover,
inconsistent time horizons, assumptions, and modeling
approaches adopted across the different studies further prohibit
comparisons with our analysis.The present economic analysis has a number of strengths and
limitations which should be noted and considered when
interpreting this analysis. In the absence of appropriate
published quality of life data or utility estimates for LGS health
states, a separate study was speciﬁcally designed to elicit
utilities for the health states of children with LGS from the UK
general public.32 The health states used in the present analysis
were not related to speciﬁc treatments and designed to
accurately reﬂect achievable treatment thresholds applied in
LGS clinical studies.
Compared with other, broader types of epilepsy, there are very
few placebo-controlled studies of LGS interventions. This is
illustrated by the identiﬁcation of only one randomized, pla-
cebo-controlled study evaluating the efﬁcacy in LGS, for each of the
three treatments assessed in the present analysis. Due the absence
of comparative clinical studies, Bayesian, mixed-treatment com-
parisons were used to indirectly assess the comparative efﬁcacy
and safety of RUF, TPM, and LTG. Providing there are no known
sources of bias, this approach has sound statistical grounds for
estimating comparative efﬁcacy in the absence of direct head-to-
head data. Bias can occur if there is an association between any
differences in patient characteristics and treatment effect.41 The
studies used for indirect or mixed-treatment comparisons in the
present analysis were similar regarding study design and patient
characteristics: the most noticeable difference being that patients
in the TPM study were receiving one to two AEDs (perhaps
indicating less severe disease), while the patients in the RUF and
LTG studies were receiving up to three concomitant AEDs.
However, for RUF, no association was found between the number
and type of AEDs received and the results of the primary efﬁcacy
analysis.59 Therefore, the differences in concomitant AED use was
not expected to represent a signiﬁcant source of bias favoring RUF
in indirect efﬁcacy and safety estimations used in the present
analysis.
When using patient populations from clinical studies to inform
health economic analyses, it is often assumed that study patient
populations are representative of populations in clinical practice.
This is a common assumption, with recognized limitations as
efﬁcacy in clinical studies may not necessarily translate into real-
life effectiveness.60 However, as LGS is a rare condition, an expert
panel was consulted to determine relatively broad LGS diagnostic
criteria and study inclusion criteria in order to enable sufﬁcient
patient recruitment in each study. As a result, it is unlikely that this
assumption would pose a signiﬁcant limitation in the present
economic analysis, especially since a recent observational study
has demonstrated that RUF shows comparable effectiveness in a
real-life setting.61
For the maintenance phase of the model, transition probabil-
ities among health states for RUF treatment were derived from the
period between three and six months in the RUF clinical study.
These transition probabilities were assumed to predict the longer
term course of LGS throughout the maintenance period. This
assumption was required as the later phase of the RUF study15 had
insufﬁcient patient numbers upon which to base an accurate
estimate. This is viewed as a valid assumption since the RUF open-
label extension did not report evidence to suggest any tolerance to
RUF, and the proportion of patients achieving 50% and 75%
reductions in seizure frequency remained comparable. The long-
term transition probabilities for RUF were also assumed to
appropriately describe the transition of patients receiving TPM
and LTG within the model. This is a conservative assumption as
three-month transition probabilities suggest that RUF is likely to
result in fewer seizures than TPM or LTG.
All models are simpliﬁcations of reality; it is not possible to
include all ramiﬁcations of a particular treatment. Therefore,
the analysis only accounted for the occurrence of adverse
L. Verdian, Y. Yi / Seizure 19 (2010) 1–1110events within the ﬁrst three months following the initiation of
any AED therapy. This is because the majority of treatment-
limiting adverse events tend to occur within the ﬁrst three
months of treatment initiation, normally resulting in treatment
switching.
The present analysis used mean AED doses reported by
clinicians, and those used in clinical studies, to calculate drug
costs. It is assumed that this represents the average consumption
of the study drugs, and that any reduced costs due to the lower
starting doses would be cancelled out by those patients receiving
higher than average doses. It was also assumed that daily doses of
RUF and concomitant AEDs, as well as other resource use,
remained the same in every three-month cycle. These are
conservative assumptions for RUF since the open-label extension
indicated that there was a decrease in the total daily dose of
concomitant AEDs for approximately half of the patients following
30 months of adjunctive treatment with RUF. Furthermore, dose
titration was also assumed not to result in additional resource use;
this may also be considered a conservative assumption given the
differences in the longer recommended titration schedules for
TPM62 and LTG.63
An expert physician survey provided an estimate of resource
use in place of a direct survey of UK clinical practice. This method
may introduce a source of subjective bias, as ideally costs due to
resource use should be based on actual data obtained in a
prospective study. However, due to constraints owing to the rare
nature of the disease, a panel of expert physicians was considered
to provide the best estimate of resource for the present cost-
effectiveness analysis.
It was also assumed that concomitant, non-comparator AED
utilization was comparable across all studies, based on the placebo
arm of the RUF clinical study.15 It must be noted that due to the
commercial availability of TPM and LTG, some patients in the
treatment and placebo arms of the RUF clinical study received TPM
and/or LTG as concomitant AEDs. However, in the model,
concomitant use of any comparator drug was removed from cost
calculations to avoid double-counting. Furthermore, the impact of
LGS treatment on premature death, costs for parents and
caregivers, and other indirect costs were not taken into account
in the analysis. Indirect costs form a substantial part of the total
costs of LGS; therefore, costs of all three treatments may have been
underestimated.
There is no separate, published long-term efﬁcacy and safety
study for LTG in a population of LGS patients. Furthermore, in the
short-term study 75% responder rates were not reported.17
However, given the importance of LTG as an existing adjunctive
therapy for LGS, and therefore as a comparator in this economic
analysis, a 75% response rate was estimated. As a result, the ICER
of RUF relative to LTG is sensitive to the probability of patients
receiving RUF achieving the WC75 health state.
Finally, the model may underestimate the incidence of adverse
events from TPM and LTG use due to the limited information on
adverse events reported in the available clinical studies.17,18 The
use of LTG is associated with the development of serious rash or
Stevens–Johnson Syndrome.64 Rash is often reported as ‘general
rash’; however, in the LTG study, rash led to the withdrawal of two
patients: one patient was hospitalized and the other was
diagnosed with Stevens–Johnson Syndrome.17 A further patient,
who was also receiving cephalosporin for pneumonia, was also
reported to have developed Stevens–Johnson Syndrome shortly
after LTG had been withdrawn. However, in the present model,
medical resource use and costs relating to general rash were
applied, rather than costs associated to more serious rash or
Stevens–Johnson Syndrome. Therefore, this may underestimate
the true costs of adverse rash events associated with LTG
treatment.5. Conclusions
The cost-effectiveness of RUF, relative to TPM and LTG, in the
treatment of LGS has been modeled as robustly as possible within
the constraints of the available data. Given the underlying
assumptions and current evidence available, the economic analysis
described demonstrates that RUF is cost-effective relative to TPM
as adjunctive therapy in LGS. Although, in the comparison with
generic LTG, the cost-effectiveness ICER of RUF exceeds the
accepted UK thresholds, there is a higher level of uncertainty
around this estimate. Given the status of LGS as an orphan disease,
and the limited treatment choices available for children with this
serious condition, RUF should be considered a feasible, effective,
and cost-effective treatment option.
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